Morphic Holding Inc represents a set of core values and corporate philosophies that drive their operations. With a focus on innovation, they are committed to pushing boundaries and delivering groundbreaking solutions in the biopharmaceutical industry. As a company, Morphic Holding Inc values integrity, transparency, and ethical practices, ensuring they uphold the highest standards in all their endeavors. By fostering a collaborative environment, they encourage teamwork, diverse perspectives, and a shared passion for making a positive impact on patients' lives. Morphic Holding Inc's dedication to excellence and patient-centric approach defines their identity and drives their pursuit of pioneering therapeutic advancements.

Morphic Holding Inc is primarily present in the United States.

Morphic Holding Inc has achieved significant milestones since its establishment. The company successfully completed its initial public offering (IPO) and listed on the Nasdaq stock exchange under the ticker symbol MORF. Moreover, Morphic Holding Inc has made notable advancements in its drug discovery research and development programs, particularly in the field of integrin-targeted therapies. This has allowed the company to progress multiple drug candidates into various stages of clinical trials, highlighting its dedication to addressing unmet medical needs. Morphic Holding Inc continues to strive for excellence in the pharmaceutical industry, constantly pushing boundaries to bring innovative treatments to patients worldwide.

Morphic Holding Inc is a reputable company specializing in the field of biotechnology. Founded in 2014, Morphic focuses on developing integrin-targeted therapeutics for chronic inflammatory and autoimmune diseases. The company boasts a talented team of scientists and researchers dedicated to advancing new treatment options. Morphic has collaborated with several renowned institutions and pharmaceutical companies to develop novel drugs targeting specific integrins, thus making significant strides in the field of biopharmaceuticals. With their rich history and strong track record, Morphic Holding Inc continues to make promising advancements in the biotechnology industry, showcasing their commitment to improving global healthcare.

The main competitors of Morphic Holding Inc in the market include pharmaceutical companies such as Biogen Inc, Amgen Inc, and Regeneron Pharmaceuticals Inc. These companies operate in the biotechnology industry and focus on developing innovative therapies and drugs for various conditions. By being aware of the competitive landscape, investors and individuals interested in Morphic Holding Inc can gain insights into the market dynamics and potential challenges the company may face.

Morphic Holding Inc is primarily active in the pharmaceutical and biotechnology industries.

The business model of Morphic Holding Inc is focused on discovering and developing oral small molecule integrin therapeutics. These therapeutics aim to treat chronic diseases by selectively targeting integrins, which are proteins involved in cell adhesion and signaling. Morphic Holding Inc's proprietary Morphic Integrin Therapeutics (MIT) platform enables the design of integrin-targeting drug candidates with improved selectivity, efficacy, and safety profiles. By leveraging their expertise in drug discovery and integrin biology, Morphic Holding Inc strives to advance potential treatments for conditions such as autoimmune diseases, fibrosis, and cancers.

P/E odnos Morphic Holding iznosi -11,84.

KUV kompanije Morphic Holding iznosi 9.473,87.

AlleAktien kvalitativni skor za Morphic Holding je 2/10.

očekivana Morphic Holding promet je 255.000,00 USD.

Dobit očekivana Morphic Holding je -204,03 mil. USD.

Morphic Holding Inc is a US-based biotechnology company focused on the discovery and development of drugs based on the science of integrin pharmacology. The company was founded in 2015 and is listed on the Nasdaq stock exchange under the symbol "MORF". This article will describe the business model of Morphic Holding Inc. Integrin pharmacology is a novel therapeutic strategy that specifically targets integrins to modulate specific cell/tissue interactions. Integrins are protein molecules on the surface of cells that are responsible for cell adhesion, cell migration, and signal transduction, making them important targets for drug development. Morphic Holding Inc has a strong portfolio of proprietary molecules that modulate integrins to treat diseases such as inflammatory bowel disease, fibrosis, cancer, pain, and autoimmune diseases. The company also has strategic partnerships with leading pharmaceutical companies such as AbbVie, Janssen, and Schrödinger to further intensify their research. Morphic's business model involves developing innovative drugs based on integrin pharmacology and licensing them to pharmaceutical companies. The company pursues a dual strategy by independently advancing its own pipeline while also demonstrating the value of its technology platform through collaborations. Morphic's product portfolio includes several drugs in development targeting fibrosis, inflammatory bowel disease, cancer, and autoimmune diseases. The lead product candidate, MORF-057, is a selective integrin α4β7 antagonist developed for the treatment of inflammatory bowel disease and is currently in Phase 2 clinical trials. Furthermore, the company recently completed the acquisition of Morphic Therapeutic Europe Limited, a company focused on researching and developing integrin-mediated tumor metastasis blockade. This acquisition expands Morphic's portfolio with innovative preclinical drug candidates for the treatment of cancer based on integrins. In summary, Morphic Holding Inc has an innovative business model based on integrin pharmacology. The company develops drugs targeting a variety of diseases by specifically modulating integrins. Their products are currently in development and have the potential to achieve significant therapeutic advancements. Through strategic partnerships and acquisitions, the company is further expanding its position in the biotechnology sector.

Morphic Holding isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Morphic Holding trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Morphic Holding je US61775R1059.

WKN od Morphic Holding je A2PLX9.

Oznaka za praćenje akcija kompanije Morphic Holding je MORF.

U poslednjih 12 meseci, Morphic Holding je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Morphic Holding će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Morphic Holding trenutno iznosi .

Morphic Holding isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Morphic Holding je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Morphic Holding se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Morphic Holding od 5. 11. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 5. 11. 2024..

Isplata poslednje dividende izvršena je 5. 11. 2024..

U godini 2023 kompanija Morphic Holding je isplatila 0 USD kao dividende.

Dividende od Morphic Holding se isplaćuju u USD.